

March 7, 2019



# Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results on March 19, 2019

VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “**Company**”) today announced that it will release its fourth quarter and full year 2018 financial results on Tuesday, March 19, 2019, after the market closes. Aurinia’s management team will host a conference call to discuss the company’s financial results for the fourth quarter and full year 2018 and to provide a general business update.

The conference call and webcast is scheduled for March 19, 2019 at 4:30pm ET. In order to participate in the conference call, please dial +1-877-407-9170 (Toll-free U.S. & Canada). An audio webcast can be accessed under "News/Events" through the "Investors" section of the Aurinia corporate website at [www.auriniapharma.com](http://www.auriniapharma.com). A replay of the webcast will be available on Aurinia’s website.

## **About Aurinia**

*Aurinia Pharmaceuticals Inc. is a late clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations impacted by serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug, for the potential treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and dry eye syndrome (DES). The company is headquartered in Victoria, British Columbia and focuses its development efforts globally. For further information, see our website at [www.auriniapharma.com](http://www.auriniapharma.com).*

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20190307005764/en/>

## **Investor Contact:**

Glenn Schulman, PharmD, MPH  
Corporate Communications  
[gschulman@auriniapharma.com](mailto:gschulman@auriniapharma.com)

or

## **Media Contact:**

Christopher Hippolyte  
212-364-0458  
[Christopher.Hippolyte@inventivhealth.com](mailto:Christopher.Hippolyte@inventivhealth.com)

Source: Aurinia Pharmaceuticals Inc.